Latest Australian Market News

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

Alcidion Group delivered positive cashflow and strong new sales in Q3 FY26, with contract expansions in the UK and Australia. The company remains on track for a significant Electronic Patient Record contract signing in May.

RLF AgTech has posted its strongest trading period with $18.3 million revenue year-to-date and positive EBITDA in March, driven by a strategic reset under new CEO Stuart Upton and a $4.5 million capital raise.

EBR Systems secures Priority Review from Australia's TGA for its wireless cardiac pacing system, fast-tracking regulatory approval and expanding access for heart failure patients. This follows strong US commercial momentum after FDA approval.

RLF AgTech has reported a record $18 million revenue for the nine months to March 2026, achieving positive EBITDA in March as it sharpens operational focus and expands its Australian sales footprint amid global fertiliser disruptions.

Heartland Group Holdings Limited maintains its FY2026 guidance, reporting expanded net interest margins and improved asset quality in 3Q2026, while navigating geopolitical uncertainties affecting New Zealand and Australian markets.

Ampol reported a robust first quarter in 2026, with refinery margins soaring to US$25.45 per barrel and production up 10%, while securing fuel supplies through May despite geopolitical tensions.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

Eagers Automotive is broadening its Australian footprint through strategic investments in multi-brand dealerships and premium Audi outlets, while advancing its international ambitions with CanadaOne Auto.

AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.

Bioxyne Ltd has secured a manufacturing agreement with global cannabis giant Aurora Cannabis, marking a major step in its international expansion of pharmaceutical-grade medicinal cannabis products.